

Human DR3-muIg Fusion Protein*

For maximal recovery of contents please quick spin vial before opening

CATALOG#: 528-020 QUANTITY: 25 µg

CONCENTRATION: 0.5 mg/ml

Molecular Structure: A soluble dimeric fusion protein consisting of the extracellular (150aa) domain of human DR3 fused to murine IgG2a Fc (233aa). Predicted non glycosylated monomeric molecular weight is 42.9 kd. N-teminal sequence: (27) GTRSP

Transfectant Cell Line: CHO

INFORMATION: Human DR3 (TRAMP, LARD) was designated TNF receptor superfamily member 25. TL1A is a ligand which can induce apoptosis through a cytoplasmic death domain similar to the CD178-CD95 (FasL-Fas) interaction. Alternatively, engagement of DR3 on T cells can synergize with other activating signals to enhance IFN_γ production. Recombinant DR3-muIg binds to recombinant TL1A in EIA.

REFERENCES:

(1) A Kaptein, et al. (2000) FEBS Lett 485:135. (2) T Migone, et al. (2002) Immunity 16:479. (3) S Targin, et al. (2004) 172: 7002.

STORAGE CONDITIONS: *Store at 2 - 5^oC*. Freeze/Thawing is not recommended.

PRODUCT STABILITY: Product should retain activity for at least 6 months after shipping date when stored as recommended. Ship Date:_____

BUFFER: 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5 mg/ml Gentamicin Sulfate (as a preservative).

PRODUCTION: Recombinant protein from (low FBS containing) tissue culture supernatant of transfectants was purified using affinity and size exclusion chromatography.

PERFORMANCE: Identity of DR3-muIg was confirmed by n-terminal sequencing: (27)GTRSP. Captured DR3-muIg was detected by anti-DR3/Biotin (catalog #250-030) in EIA.

*Research use only. Not for use in Diagnostic procedures.